EGFR and cancer: Clinically, EGFR is a prognostic marker and an effective therapeutic target of multiple human cancers, especially NSCLC.21 However, it is well known that the EGFR inhibitors widely face primary resistance (~60%) and rapidly generate acquired resistance (6–12 months).22, 23 Therefore, the downstream effector function of EGFR may act as a substitutable therapeutic target of EGFR to overcome the drug resistance.24, 25 The previous study26 showed that EGFR inhibition attenuated liver fibrosis and the development of hepatocellular carcinoma.